Research Analysts Set Expectations for KALV FY2029 Earnings

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) – Stock analysts at HC Wainwright cut their FY2029 earnings estimates for KalVista Pharmaceuticals in a research note issued to investors on Friday, December 6th. HC Wainwright analyst A. Fein now anticipates that the specialty pharmaceutical company will post earnings of $1.24 per share for the year, down from their prior estimate of $1.36. HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for KalVista Pharmaceuticals’ current full-year earnings is ($2.70) per share.

Other equities analysts have also recently issued reports about the company. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. Cantor Fitzgerald restated an “overweight” rating on shares of KalVista Pharmaceuticals in a research report on Monday.

KalVista Pharmaceuticals Trading Up 1.1 %

KALV stock opened at $9.44 on Monday. The firm has a 50 day moving average of $10.81 and a 200-day moving average of $11.80. The company has a market cap of $466.52 million, a price-to-earnings ratio of -2.59 and a beta of 0.85. KalVista Pharmaceuticals has a 12-month low of $7.39 and a 12-month high of $16.88.

Insider Transactions at KalVista Pharmaceuticals

In related news, CEO Benjamin L. Palleiko sold 14,400 shares of the company’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $133,344.00. Following the completion of the transaction, the chief executive officer now directly owns 266,598 shares in the company, valued at approximately $2,468,697.48. This represents a 5.12 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Paul K. Audhya sold 8,077 shares of the stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $9.26, for a total value of $74,793.02. Following the transaction, the insider now owns 94,199 shares in the company, valued at $872,282.74. This trade represents a 7.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 32,291 shares of company stock worth $304,086 over the last ninety days. 10.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On KalVista Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. nVerses Capital LLC purchased a new stake in shares of KalVista Pharmaceuticals during the 2nd quarter valued at $25,000. China Universal Asset Management Co. Ltd. grew its position in KalVista Pharmaceuticals by 67.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 8,286 shares of the specialty pharmaceutical company’s stock valued at $96,000 after acquiring an additional 3,328 shares during the period. Intech Investment Management LLC purchased a new stake in KalVista Pharmaceuticals during the third quarter valued at about $126,000. SG Americas Securities LLC acquired a new stake in KalVista Pharmaceuticals during the third quarter worth about $153,000. Finally, Quest Partners LLC purchased a new position in shares of KalVista Pharmaceuticals in the 3rd quarter worth about $175,000.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).